ArticleJournal of Cancer2025

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.

Ryan J Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.